1. A global strategy for malaria control, Geneva, World Health Organization: Geneva, 1993.

2. Bloland PB et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. Journal of Infectious Diseases, 1993 167(4):932-937.

3. Bloland PB, Ettling M. Making malaria treatment policy in the face of drug resistance. Annals of Tropical Medicine and Parasitology, 1999, 93(1):5-23.

4. Marsh K et al. Malaria disaster in Africa. Lancet, 1998, 352:924.

5. Winstanley P, Brekenridge A. Therapeutics and drug development. Lancet, 1997, 349(Suppl. 1):3-4.

6. Krause G et al. Performance of village pharmacies and patient compliance after implementation of an essential drug programme in rural Burkina Faso. Health Policy and Planning, 1998, 13(2):159-166.

7. Foster SDF. The distribution and use of antimalarial drugs - not a pretty picture. In: Targett GAT, ed. Malaria: waiting for the vaccine. Chichester, John Wiley & Sons Ltd., 1991:123-128.

8. White N. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society of London, 1999, B(354):739-749.

9. White NJ et al. Averting a malaria disaster. Lancet, 1999, 353:1965-1967.

10. White NJ. Delaying antimalarial drug resistance with combination therapy. Parassitologia, 1999, 41:301-308.

11. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates, 1998, 1:3-9.

12. The use of artemisinin and its derivatives as antimalarial drugs: report of a joint CTD/DMP/TDR informal consultation. Geneva, World Health Organization, 1998 unpublished document WHO/MAL/98.1086)

13. Price RN et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet, 1996, 347:1654-1658.

14. Framework for developing, implementing and updating antimalarial treatment policy in Africa. A guide for country malaria control programmes. Harare, World Health Organization Regional Office for Africa, 2000.

15. World Health Organization. Severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine & Hygiene, 2000, 94(Suppl. 1):S1-S90.

16. Management of uncomplicated malaria and the use of antimalarial drugs for the protection of travellers. Geneva, World Health Organization, 1997 (unpublished document WHO/MAL/96.1075).

17. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. Geneva, World Health Organization, 1973 (WHO Technical Report Series, No. 529).

18. Peters W. Chemotherapy and drug resistance in malaria. London, Academic Press, 1987.

19. Peters W. The prevention of antimalarial drug resistance. Pharmacology and therapeutics, 1990, 47: 497-508.

20. Su X et al. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine resistant P. falciparum in Southeast Asia and Africa. Cell, 1997, 91(5):593-603.

21. Triglia T et al. Mutations in DHFS are responsible for sulfone and sulfonamine resistance in P. falciparum. Proceedings of the National Academy of Science USA, 1997, 94(25):13944-13949.

22. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87:75-78.

23. Trape JF et al. Impact of chloroquine resistance on malaria mortality. Comptes rendu de l’Académie des Sciences, 1998, 321(Series III):689-697.

24. Greenberg AF et al. Hospital based surveillance of malaria related paediatric morbidity and mortality in Kinshasa, Zaire. Bulletin of the World Health Organization, 1989, 67(2):189-196.

25. Chemotherapy of malaria. Report of Scientific Group. Geneva, World Health Organization, 1967 (WHO Technical Report Series, No. 375).

26. Bruce-Chwatt, L.J. et al. Chemotherapy of malaria, revised 2nd ed., World Health Organization, Geneva, 1987.

27. Prasad RN et al. Application of a simplified in vivo test system for determining chloroquine resistance in Plasmodium falciparum. Bulletin of the World Health Organization, 1990, 68:755-75.

28. Rieckman KH. Monitoring the response of malaria infections to treatment. Bulletin of the World Health Organization, 1990, 68:759-760.

29. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission. Geneva, World Health Organization, 1996

30. Olliaro P et al. Systematic review of amodiaquine treatment in uncomplicated malaria [See Comments]. Lancet, 1996, 348:1196-1201.

31. Suebsaeng L, Wernsdorfer WH, Rooney W. Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand. Bulletin of the World Health Organization, 1986, 64(5): 759-765.

32. Cerutti Jr, C et al. In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil Journal of Infectious Diseases, 1999, 180:2077-2080.

33. Basco LK et al. Activity in vitro of chloroquine, cycloguanil and mefloquine against African isolates of Plasmodium falciparum: presumptive evidence for chemoprophylactic efficacy in Central and West Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89:657-658.

34. Bunnag D et al. Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 1991, 22(4):539-543.

35. Bunnag D et al. Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 1991, 22(4):534-538.

36. Bunnag D et al. Intramuscular artemether in female patients with uncomplicated falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 1993, 24(1):49-52.

37. Bunnag D, Karbwang J, Harinasuta T. Artemether in the treatment of multiple drug resistant falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 1992, 23(4):762-767.

38. Luxemburger C et al. Oral artesunate in the treatment of uncomplicated hyperparasitic falciparum malaria. American Journal of Tropical Medicine and Hygiene, 1995, 53(5):522-535.

39. Hien TT. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam. Transactions of the Royal Society of Tropical Medcine and Hygiene, 1994, 88(Suppl. 1):S7-S8.

40. Murphy GS et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet, 1993, 341:96-100.

41. Alecrim M et al. Description of a possible clonal expansion of Plasmodium vivax in Manaus-Amazonas-Brazil. Revista da Sociadade Brasiliera de Medicina Tropical, 1999, 32:303-305.

42. Rodriguez RM. Eficacia terapéutica de la cloroquina en la malaria por Plasmodium vivax. Parroquia El Dorado, Municipio Sifontes, estado Bolívar, Venezuela. In: Escuela de Medicina. Bolivar, Universidad de Oriente, 1999.

43. Paez E et al. Evaluation of in vivo response of Plasmodium vivax to chloroquine and primaquine in Sifontes, Bolivar State, Venezuela. In: XV International Congress of Tropical Medicine and Malaria. Venezuela, 2000.

44. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination therapy for malaria. Parasitology Today, 1996, 12(10):399-401.

45. Price R et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene, 1999, 60:547-555.

46. Price RN et al. Artesunate-mefloquine treatment of 1967 patients with multi-drug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91:574-577.

47. White NJ. Minireview: assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial Agents and Chemotherapy, 1997, 41(7):1413-1422.

48. WHO, Informal consultation on the neurological investigations required for patients treated with artemisinin compounds and derivatives. Geneva, World Health Organization, 1998.

49. Brockman A et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94: 537-544.

50. Cot M et al. Increase in birth weight following chloroquine chemoprophylaxis during the first preg-nancy: results of a randomized trial in Cameroon. American Journal of Tropical Medicine and Hygiene, 1995, 53:581-585.

51. Parise ME et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. American Journal of Tropical Medicine and Hygiene, 1998, 59: 813-822.

52. Shulman CE et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet, 1999, 353:632-636.

53. Verhoeff FH et al. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Annals of Tropical Medicine and Parasitology, 1998, 92:141-150.

54. International travel and health. Vaccination requirements and health advice. Geneva, World Health Organization, 2000.

55. Saxe SE, Gardner P. The returning traveller with fever. Infectious Disease Clinics of North America, 1992, 6:427-439.

56. Catmat T. Canadian recommendations for the prevention and treatment of malaria among international travellers. Canada Communicable Disease Report, 2000, 26S2:(Suppl.).

57. Houston S, Keystone JS, Kain KC. Mefloquine to prevent malaria. Mefloquine remains the best drug. British Medical Journal, 1998, 316:1980-1981.

58. Jaeger A et al. Clinical features and management of poisoning due to antimalarial drugs. Medical Toxicology and Adverse Drug Experience, 1987, 2:242-273.

59. Baird K et al. Randomised, double-blind, placebo controlled evaluation of Malarone for prophylaxis of P. vivax and P. falciparum in non-immune transmigrants to Irian Jaya. ASTM Standardization News, Houston, TX, 2000.

60. Baird JK et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1995, 52(6):479-484.

61. Lobel HO et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet, 1993, 341:848-851.

62. Steffen R et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet, 1993, 341:1299-1303.

63. Heusser R et al. Malaria prophylaxis and self-care-problems and current solutions. Schweizerische Rundschau für Medizin Praxis, 1991, 80(4):49-52.

64. Schlagenhauf P, Steffen R. Stand-by treatment of malaria in travellers: a review. Journal of Tropical Medicine and Hygiene, 1997, 97(3):151-160.

65. Junghanss T. Principles and practice of malaria chemoprophylaxis and of malaria emergency medication for travellers. Schweizerische Rundschau für Medizin Praxis, 1993, 82(5):130-138.

66. Mittelholzer ML, Sturchler D. Emergency treatment of malaria during travel. Schweizerischea Rundschau für Medizin Praxis, 1993. 82(35):938-940.

67. Schlagenhauf P. Textbook of Travel Medicine, 2nd ed., 2000.

68. Schuurkamp GJ et al. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86(2):121-122.

69. Singh J et al. Antirelapse treatment with primaquine and pyrimethamine. Indian Journal of Malariology, 1954, 8:127-136.

70. Valecha N et al. Comparative antirelapse activity of CDRI compound 80/53 (Bulaquine) vs. primaquine in double blind clinical trial. Current Science, in press.

71. Georgiev GD, Kielstrup RW. Blister calendar packs - potential improvement in the supply and utilisation of multiple drug therapy in leprosy control programmes. International Journal of Leprosy, 1988, 56(4):603-610.

72. Revankar CR, Dhamale CB, Ganapati R. Experience of multidrug therapy blister-calender packs in an urban leprosy control programme in Bombay [letter]. Leprosy Review, 1991, 62(3):336-342.

73. Wiseman LA. Calender (blister) packs for multiple drug therapy in leprosy: an inexpensive locally produced version [letter]. Leprosy Review, 1987, 64:250-254.

74. Shwe T, Lwin M, Aung S. Influence of blister packaging on the efficacy of artesunate and quinine + tetracycline treatment of uncomplicated malaria in Thailand. Bulletin of the World Health Organization, 1998, 76(Suppl. 1):59-66.

75. Qingjun L et al. The effect of drug packaging on patients’ compliance with treatment for Plasmodium vivax malaria in China. Bulletin of the World Health Organization, 1998, 76(Suppl. 1):21-27.

76. The advantages of pre-packaged materials. TDR news, 1997, 54:5.

77. Barnish G. Meeting on the packaging of antimalarials in Africa. Liverpool, Tropical Diseases and Health Sector Reform Task Force and Liverpool School of Tropical Medicine, 1997.

78. Cullinan TR, Pieterick C. Packaged treatment for first line care in cerebral malaria and meningitis. Geneva, World Health Organization, 1997 (unpublished document WHO/MAL/97.1083).

79. Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and the management of malaria in pregnancy. Geneva, World Health Organization, 1994 (unpublished document WHO/MAL/94.1070).

80. Quick JD et al. eds. Management Sciences for Health (MSH). and the World Health Organization (WHO), managing drug supply, 2nd ed. Hartford, CT, Kumaria Press, 1997.

81. The use of essential drugs. Geneva, World Health Organization, 2000 (WHO Technical Report Series, No. 895).

82. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Safety, 1996, 14(3):131-145.

83. Coopman SA et al. Cutaneous disease and drug reactions in HIV infection [See Comments]. New England Journal of Medicine, 1993, 328: 1670-1674.

84. Abdulla S et al. The costs, effects and cost-effectiveness of changing the first line drug for the treatment of malaria in Tanzania. 2000 (report submitted to the Ministry of Health, United Republic of Tanzania and WHO Regional Office for Africa).

85. Goodman C, Coleman P, Mills A. Economic analysis of malaria control in sub-Saharan Africa. Geneva, Global Forum for Health Research, 2000.

86. Hausmann-Muela S, Muela-Ribera JM, Tanner M. Fake malaria and hidden parasites-the ambiguity of malaria. Anthropology and Medicine, 1998, 5(1):43-61.

87. Bjorkman A, Phillips-Howard PA. Drug resistant malaria: mechanisms of development and inferences for malaria control. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84(3):323-324.

88. Foster S. Treatment of malaria outside the formal health services. Journal of Tropical Medicine and Hygiene, 1995, 98(1):29-34.

89. Ndyomugyenyi R, Neema S, Magnussen P. The use of formal and informal services for antenatal care and malaria treatment in rural Uganda. Health Policy and Planning, 1998, 1:94-102.

90. Ongore D, Nyabola L. Role of shops and shopkeepers in malaria control. East African Medical Journal, 1996, 6:390-394.

91. Snow RW et al. The role of shops in the treatment and prevention of childhood malaria on the coast of Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86(3):237-239.

92. Nyamongo IK. Home case management of malaria: an ethnographic study of lay people’s classification of drugs in Suneka division, Kenya. Tropical Medicine and International Health, 1999, 4:736-743.

93. Nsimba SE et al., A household survey of source, availability, and use of antimalarials in a rural area of Tanzania. Drug Information Journal, 1999, 33:1025-1032.

94. Mwenesi HT et al. Child malaria treatment practices among mothers in Kenya. Social Science and Medicine, 1995, 40:1271-1277.

95. Ofori-Adjei D, Arnhinful DK. Effect of training on the clinical management of malaria by medical assistants in Ghana. Social Science and Medicine, 1996, 42(8):1141-1153.

96. Nicholas DD et al. The quality assurance project: introducing quality improvement to primary health care in less developed countries. Quality Assurance in Health Care, 1991, 3(3):147-165.

97. Kitua AY. Antimalarial drug policy: making systematic change. Lancet, 1999, 354(Suppl. IV):32.

98. Brugha R et al. Viewpoint: management of malaria - working with the private sector. Tropical Medicine and International Health, 1999, 4:402-406.

99. Baird JK et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1991, 44(5):547-552.

100. Collignon P. Chloroquine resistance in Plasmodium vivax [letter]. Journal of Infectious Diseases, 1991, 164(1):222-223.

101. Myat Phone K et al., Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87(6):687.

102. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet, 1989, 2:1183-1184.

103. Schuurkamp GJ. The epidemiology of malaria and filariasis in the Ok Tedi region of Western Province, Papua New Guinea. Port Moresby, University of New Guinea, 1992.

104. Whitby M et al. Chloroquine-resistant Plasmodium vivax [letter]. Lancet, 1989, 2:1395.

105. Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America [See Comments]. Clinical and Infectious Diseases, 1996, 23(5):1171-1173.

106. Sexton JD et al. Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. American Journal of Tropical Medicine and Hygiene, 1988, 38(2):237-243.

107. Ward SA et al. Optimal dosage of chloroquine for malaria prophylaxis. In: Abstracts of the Sixth Conference of the International Society of Travel Medicine. Montreal Convention Centre, 1999.

108. Steffen R et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bulletin of the World Health Organization. 1990, 68(3):313-322.

109. Advances in malaria chemotherapy. Report of a WHO Scientific Group. Geneva, World Health Organization, 1984 (WHO Technical Report Series No. 711).

110. Practical chemotherapy of malaria. Report of a WHO Scientific Group. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No. 805).

111. Brasseur P et al. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93(6):645-650.

112. Fadat G et al. Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet, 1991, 338:1092

113. van Dillen J et al. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93(2):185-188.

114. Gorissen E et al. In vivo efficacy study of amodiaquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Tropical Medicine and International Health, 2000, 5(6):459-463.

115. Hatton CS et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet, 1986, 1:411-414.

116. Neftel KA et al. Amodiaquine induced agranulocytosis and liver damage. British Medical Journal (Clinical research ed.), 1986, 292:721-723.

117. Steffen R, Heusser R. The reliability and side effects of malaria chemoprophylaxis. Schweizerischer Rundschau für Medizin Praxis, 1986, 75(16):446-448.

118. Freyenmuth T. Agranulocytose und Leberschädigung durch Amodiaquine. Zurich, University of Zurich (PhD thesis), 1987.

119. WHO Expert Committee on Malaria. Nineteenth report. Geneva, World Health Organization, 1992 (unpublished document WHO/CTD/92.1)

120. Rovieux B et al., Amodiaquine induced agranulocytosis. British Journal of Haematology, 1989, 71:7-11.

121. Aymard JP et al. Agranulocytose aigue a l’amodiaquine. Therapie, 1987, 42:359-364.

122. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain [see Comments]. Journal of the Royal Society of Medicine, 1990, 83(2):82-85.

123. Winstanley PA et al. The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. British Journal of Clinical Pharmacology, 1990, 29(4):479-485.

124. Winstanley PA et al. The disposition of amodiaquine in Zambians and Nigerians with malaria. British Journal of Clinical Pharmacology, 1990, 29(6):695-701.

125. Mengesha T, Makonnen E. Comparative efficacy and safety of chloroquine and alternative anti-malarial drugs: a meta-analysis from six African countries. East African Medical Journal, 1999, 76(6):314-319.

126. Hengy G et al. Accès palustres simples en zone de haut niveau de résistance à la chloroquine; 2 Evaluation de schémas thérapeutiques de première intention. Bulletin de la Societé de Pathologie Exotique, 1990, 83:53.

127. Nevill CG et al. A comparison of amodiaquine and chloroquine in the treatment therapy of falciparum malaria in Kenya. East African Medical Journal, 1994, 71(3):167-170.

128. Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metabolism Review, 1990, 22(1):87-144.

129. Fidock DA Wellems TE. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proceedings of the National Academy of Science, USA, 1997, 94:10931-10936.

130. Ogutu RB et al. The efficacy of pyrimethamine-sulphadoxine resistance of Plasmodium falciparum malaria in Kenyan children. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94:83-84.

131. Trigg JK et al. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Tropica, 1997, 63:185-189.

132. Ronn AM et al. High level of resistance of Plasmodium falciparum to sulfadoxine- pyrimethamine in children in Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90(2):179-181.

133. Onyiorah E et al. Early clinical failures after pyrimethamine-sulfadoxine treatment of uncomplicated malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90:307-308.

134. Kazembe P. The process of antimalarial drug policy change from chloroquine to SP in Malawi. Geneva, World Health Organization, 2000 (Informal Consultation on the Use of Antimalarial Drugs, working paper).

135. Kitua A et al., Report of the Tanzania Ministry of Health Task Force on Antimalarial Drug Policy. Geneva, World Health Organization, 2000 (Informal Consultation on the Use of Antimalarial Drugs, working paper).

136. Doberstyn EB et al. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1979, 73(1):15-17.

137. Kebede D. The process of development of a national antimalarial drug policy in Ethiopia. Geneva, World Health Organization, 2000 (Informal Consultation on the Use of Antimalarial Drugs, working papaer)

138. Boele van Hensbroek M et al. Iron but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89:672-676.

139. Schultz LJ et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. American Journal of Tropical Medicine and Hygiene, 1994, 51:515-522.

140. Steketee RW et al. Malaria prevention in pregnancy: the effects of treatment and chemoprophylaxis on placental infection, low birth weight, and fetal, infant and child survival. United States Department of health and Human Services, 1994 (CDC/ARTS (99-4048)).

141. Pyrimethamine combinations in pregnancy. Lancet, 1983, 2:1005-1007.

142. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 4th ed., Baltimore, MD, Williams and Wilkins, 1998.

143. Wernsdorfer WH, Trigg PI. Recent progress of malaria research: chemotherapy. In: Mcgregor WHW, ed. Malaria: principles and practice of malariology, Edinburgh, Churchill Livingstone, 1988:1569-1674.

144. Dost FH, Gladtke E. [Pharmacokinetics of 2-sulfanilamido-3-methoxy pyrazine in children (elimi-nation, enteral absorption, distribution and dosage)]. Arzneimittelforschung, 1969, 19(8):1304-1307 [in German].

145. Miller KD et al. Severe cutaneous reactions among American travelers using pyrimethamine- sulfa-doxine (Fansidar) for malaria prophylaxis. American Journal of Tropical Medicine and Hygiene, 1986, 35(3):451-458.

146. Looareesuwan S et al., Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 1996, 54(1):62-66.

147. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drug against Plasmodium falciparum in vitro. Experimental Parasitology, 1995, 80:373-381.

148. Mberu EK et al. Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89(6):658-659.

149. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proceedings of the National Acadamy of Science, USA, 1990, 87(8):3018-3022.

150. Plowe CV et al. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. American Journal of Tropical Medicine and Hygiene, 1995, 52(6):565-568.

151. Black RH et al. Malaria in the Australian army in South Viet Nam: successful use of a proguanil dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. Medical Journal of Australia. 1973, 26:1265-1270.

152. Jamaludin A et al., Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. Tropical Medicine and Parasitology, 1990, 41(3):268-272.

153. Na-Bangchang, K et al., Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2000, 55(10):743-748.

154. Navaratnam V et al. Comparative pharmacokinetics of two commercial formulations of mefloquine. In: Vth World Conference in Clinical Pharmacology and Therapeutics. Yokohama, 1992.

155. Fontanet AL et al. High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. Bulletin of the World Health Organiaztion, 1993, 71:377-383.

156. Thaithong S, Beale GH, Chutmongkonkul M. Variability in drug susceptibility amongst clones and isolates of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82(1):33-36.

157. ter Kuile FO et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bulletin of the World Health Organization, 1995, 73(5):631-642.

158. White NJ. Drug resistance in malaria. British Medical Bulletin, 1998, 54(3):703-715.

159. Swartz DE et al. Mefloquine absorption half-life from the commercial tablet Ro 21-5998/603. Solubility of the hydrochloride considered as a possible limiting factor to influence the rate and extent of absorption. 1986 (Roche research report, No. 8-153’133).

160. Crevoisier C, Tillement JP, Barre J. Food increases the bioavailibility of mefloquine. In: Proceedings of the XIIth International Congress of Tropical Medicine and Malaria, Jomtien, Pattaya, Thailand, 1992. 1992: 268 (Abstract ThP7-1).

161. Nosten F. Vincenti M, Simpson J. The effects of mefloquine treatment in pregnancy. Clinical and Infectious Diseases, 1999, 28:808-815.

162. Luxemburger C et al. Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(5):562-563.

163. Croft AM, Garner P. Mefloquine for preventing malaria in non-immune adult travellers. Cochrane Database System Review, 2000, CD000138(2).

164. Evans MR et al. Prevention and treatment of malaria in UK travellers. Hospital Medicine, 2000, 61(3):162-166.

165. Boudreau E et al. Tolerability of prophylactic Lariam regimens. Tropical Medicine and Parasitology, 1993, 44(3):257-265.

166. Vanhauwere B et al. Post-marketing surveillance of prophylactic mefloquine (Larium) use in preg-nancy. American Journal of Tropical Medicine and Hygiene, 1998, 58:17-21.

167. Phillips-Howard PA et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. Journal of Travel Medicine, 1998, 5:121-126.

168. Edstein MD, Veenendaal JR, Hyslop R. Excretion of mefloquine in human breast milk. Chemotherapy, 1988, 34(3):165-169.

169. Karbwang J, White NJ, Clinical pharmacokinetics of mefloquine. Clinical Pharmacokinetics, 1990, 19(4):264-279.

170. Martin C et al., Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. European Journal of Clinical Pharmacology, 1994, 47(1):85-87.

171. Havaldar PV, Mogale KD. Mefloquine induced psychosis. Paediatric Infectious Diseases, 2000, 19:166-167.

172. Potasman I et al. Neuropsychiatric problems in 2,500 long-term travelers to the tropics. Journal of Travel Medicine, 2000, 7(1):5-9.

173. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety, 1995, 12(6):370-383.

174. Weinke T et al. Neuropsychiatric side effects after the use of mefloquine. American Journal of Tropical Medicine and Hygiene, 1991, 45(1):86-91.

175. Sowunmi A et al. Neuropsychiatric side effects of mefloquine in Africans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87(4):462-463.

176. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985-1990). Geneva, World Health Organization, 1991 (unpublished document WHO/MAL/91.1063).

177. Bem JL et al. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. Journal of Tropical Medicine and Hygiene, 1992, 95(3):167-179.

178. Phillips MA et al. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. Journal of Travel Medicine, 1996, 3(1):40-45.

179. Vuurman E et al. Effects of mefloquine, alone and with alcohol on psychomotor and driving performance. European Journal of Clinical Pharmacology, 1996, 50(6):475-485.

180. International reporting of adverse reactions. Geneva, Council for International Organizations of Medical Sciences, 1990:66.

181. International reporting of periodic-safety update summaries. Geneva, Council for International Organizations of Medical Sciences, 1992:36.

182. Guidelines for preparing core clinical-safety information on drugs. Geneva, Council for International Organizations of Medical Sciences, 1995:69.

183. Barrett PJ et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers [See Comments]. British Medical Journal, 1996, 313:525-528.

184. Ekue JMK et al. A double blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bulletin of the World Health Organization, 1983, 61:713-718.

185. Nosten F et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet, 1993, 341:1054-1056.

186. Karbwang J et al., Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria. Bulletin of the World Health Organization, 1994, 72(2):233-238.

187. Davis TME. Safety of mefloquine in healthy volunteers: a double blind, placebo-controlled trial. In: Mefloquine (Lariam) in special situations: New data. Fourth International Conference on Travel Medicine, Acapulco, Mexico, 23-27 April, 1995:4.

188. International travel and health: vaccination requirements and health advice. Geneva, World Health Organization, 1996:104.

189. Danis M et al. [Blackwater fever after ingestion of mefloquine. Three cases (letter)]. Presse médicale, 1993, 22(2):80 [in French].

190. McBride SR et al. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet, 1997, 349: 101.

191. Martin GJ et al. Exfoliative dermatitis during malarial prophylaxis with mefloquine [letter]. Clinical and Infectious Diseases, 1993, 16(2):341-342.

192. Van den Enden E et al. Mefloquine-induced Stevens-Johnson syndrome [letter]. Lancet, 1991, 337:683.

193. Shlim DR. Severe facial rash associated with mefloquine [letter]. Journal of the American Medical Association, 1991, 266(18):2560.

194. Scerri L, Pace JL, Mefloquine-associated cutaneous vasculitis. International Journal of Dermatology, 1993, 32(7):517-518.

195. Patchen LC et al. Neurologic reactions after a therapeutic dose of mefloquine [letter]. New England Journal of Medicine, 1989, 321(20):1415-1416.

196. Schlagenhauf P et al. Tolerance of mefloquine by SwissAir trainee pilots. American Journal of Tropical Medicine and Hygiene, 1997, 56(2):235-240.

197. Hessen-Soderman AC et al. Hearing, postural control and vestibular functions during mefloquine prophylaxis. In: Programs and abstracts of the Fourth International Conference on Travel Medicine. Acapulco, Mexico, April 23-27, 1995. 1995:87.

198. Karbwang J et al. Effect of ampicillin on mefloquine pharmacokinetics in Thai males. European Journal of Clinical Pharmacology, 1991, 40(6):631-633.

199. Karbwang J et al. Effect of tetracycline on mefloquine pharmacokinetics in Thai males. European Journal of Clinical Pharmacology, 1992, 43(5):567-569.

200. Bjorkman A et al. Susceptibility of P. falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia. Bulletin of the World Health Organization, 1991, 69(4):459-465.

201. Wanwimolruk S et al. Pharmacokinetics of quinine in young and elderly subjects. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85(6):714-717.

202. World Health Organization, Division of Control of Tropical Diseases. Severe and complicated malaria [see Comments]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84(Suppl
2):1-65.

203. Winstanley PA et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration [see comments]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87(2):201-206.

204. Supanaranond W et al. Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. European Journal of Clinical Pharmacology, 1993, 44(4):325-329.

205. Bunnag D et al. A combination of quinine, quinidine and cinchonine (LA 40221) in the treatment of chloroquine resistant falciparum malaria in Thailand: two double-blind trials. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83(1):66.

206. Basco LK, Le Bras J. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 1992, 47(4):521-527.

207. Basco LK, Le Bras J. In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halo-fantrine, pyronaridine and artemisinin derivatives. Annals of Tropical Medicine and Parasitology, 1994, 88(2):137-144.

208. Peters W et al. The chemotherapy of rodent malaria. XLII. Halofantrine and halofantrine resistance. Annals of Tropical Medicine and Parasitology, 1987, 81(5):639-646.

209. Nateghpour M et al. Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 1993, 37(11):2337-2343.

210. Horton RJ. Halofantrine treatment of acute falciparum malaria in infants and young children. Mitteilungen der Osterreichischen Gesellschaft für Tropenmedizin und Parasitologie, 1994, 16:87-92.

211. Humberstone AJ et al. Effect of altered serum lipid concentrations on the IC50 of halofantrine and Plasmodium falciparum. Journal of Pharmaceutical Science, 1998, 87(2):256-258.

212. Milton KA et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. British Journal of Clinical Pharmacology, 1989, 28(1):71-77.

213. Shanks GD et al. Halofantrine given with food for falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86(3):233-234.

214. Monlun E et al. Cardiac complications of halofantrine: a prospective study of 20 patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89(4):430-433.

215. Schuster BG, Canfield CJ. Preclinical studies with halofantrine. In: Halofantrine in the treatment of multidrug resistant malaria. Parasitology Today, 1989, Suppl:65-79.

216. Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clinical Pharmacokinetics, 1994, 27(2):104-119.

217. Sowunmi A et al. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(4):446-448.

218. Gundersen SG et al. Halofantrine-associated ventricular fibrillation in a young woman with predisposing QTc prolongation. Scandinavian Journal of Infectious Diseases, 1997, 29(2):207-208.

219. Malvy D et al. Fatal cardiac incident after use of halofantrine. Journal of Travel Medicine, 2000, 7(4):215-216.

220. Castot A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine [letter; comment]. Lancet, 1993, 341:1541.

221. Mojon M et al., Intravascular haemolysis following halofantrine intake. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88(1):91.

222. McIntosh HM, Olliaro P. Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database System Review, 2000, CD000256(2).

223. Yang HL et al. In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas. Southeast Asian Journal of Tropical Medicine and Public Health, 1997, 28(3): 460-464.

224. Doherty JF et al. A randomized safety and tolerability trial of artesunate plus sufladoxine- pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93(5): 543-546.

225. von Seidlein L et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children; a double-blind, randomised, controlled trial. Lancet, 2000, 355:352-357.

226. Qinghaosu ACC. Antimalarial studies on qinghaosu. Chinese Medical Journal, 1979, 92:811-816.

227. Li GQ et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88 (Suppl. 1):S5-S6.

228. Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (qinghaosu) and artemether in treating malaria in pregnant woman. Journal of Traditional Chinese Medicine, 1989, 9(1):28-30.

229. McGready R et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92:430-433.

230. Li Q-G et al. The pharmacokinetics and bioavailability of dihydroartemisinin arteether, artemether, artesunic and arteline acid in rats. Journal of Pharmacy and Pharmacology, 1998, 50:173-182.

231. Navaratnam V et al. Pharmacokinetics of artemisinin-type compounds. Clinical Pharmacokinetics. 2000, 39(4):255-270.

232. Petras JM et al. Brain injury induced in Rattus rattus by the antimalarial drug arteether (AE): a neuroanatomical and neuropathological analysis. Anatomical Record, 1993, 237(Suppl. 1):95.

233. Genovese RF et al. Arteether neurotoxicity in the absence of deficits in behavioural performance in rats. Annals of Tropical Medicine and Parasitology, 1995, 89(4):447-449.

234. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Medeciene Tropicale (Mars), 1998, 58(Suppl. 3):50-53.

235. Hien TT,White NJ. Qinghaosu [see comments]. Lancet, 1993, 341:603-608.

236. Kissinger E et al. Clinical and neuro-physiological study of the effects of multiple doses of artemisinin on brain stem function in Vietnamese patients. American Journal of Tropical Medicine and Hygiene, 2001, in press.

237. van Vugt M et al. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2000, 62(1):65-69.

238. Davis TM et al. Artesunate and cerebellar dysfunction in falciparum malaria. New England Journal of Medicine, 1997, 337(11):792.

239. Gachot B et al. Artesunate and cerebellar dysfunction in falciparum malaria. New England Journal of Medicine, 1997, 337(11):792.

240. The role of artemisinin and its derivatives in the current treatment of malaria (1994-1995). Geneva, World Health Organization, 1994 (unpublished document, WHO/MAL/94.1067).

241. Hien, TT et al. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86(6):582-583.

242. Cao XT et al. Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91(3):335-342.

243. White NJ, Olliaro P. Artemisinin and derivatives in the treatment of uncomplicated malaria. Medeciene Tropicale (Mars), 1998, 58(Suppl. 3):54-56.

244. McIntosh HM, Olliaro P. Treatment of uncomplicated malaria with artemisinin derivatives. A systematic review of randomised controlled trials. Medeciene Tropicale (Mars), 1998, 58(Suppl.
3):57-58.

245. Le NN et al. Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91(2):191-194.

246. Bich NN et al. Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 1996, 55(4):438-443.

247. Hien TT et al. Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88:688-691.

248. Ashton M et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clinical Pharmacology and Therapeutics, 1998, 63(4):482-493.

249. De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs, 1996, 52(6):818-836.

250. De Vries PJ et al. The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. Journal of Tropical Medicine and Hygiene, 1997, 56(5):503-507.

251. Sidhu JS et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 1998, 5(4):347-354.

252. Koopmans R et al. The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(4):434-436.

253. Ha V et al. Severe and complicated malaria treated with artemisinin, artesunate or artemether in Viet Nam. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91(4):465-467.

254. Nosten F. Artemisinin: large community studies. Transactions of the royal Society of Tropical Medicine and Hygiene, 1991, 88(Suppl. 1):45-49.

255. Karbwang J et al. Artemether 5 versus 7 day regimen for severe falciparum malaria. South East Asian Journal of Tropical Medicine and Public Health, 1994, 25(4):702-706.

256. Bunnag D et al. Two doses of artemether/mefloquine or artesunate/mefloquine combination for multidrug resistant falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 1997, 28(4):727-730.

257. Na-Bangchang K et al. Compliance with a 2 day course of artemether-mefloquine in an area of high-ly multi-drug resistant Plasmodium falciparum malaria. British Journal of Clinical Pharmacology, 1997, 43(6):639-642.

258. Price RN et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89(5):523-527.

259. Na Bangchang K et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 1994, 37(3):249-253.

260. Teja-Isavadharm P et al. Comparative bioavailability of oral, rectal and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. British Journal of Clinical Pharmacology, 1996, 42(5):599-604.

261. Karbwang J et al. Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure. British Journal of Clinical Pharmacology, 1998, 45(6):597-600.

262. Brewer TG et al. Fatal neurotoxicity of arteether and artemether. American Journal of Tropical Medicine and Hygiene, 1994, 51(3):251-259.

263. Looareesuwan S et al. Comparative clinical trial of artesunate followed by mefloquine in the treatment of acute uncomplicated falciparum malaria: two-and three-day regimens. American Journal of Tropical Medicine and Hygiene, 1996, 54(2):210-213.

264. Karbwang J et al. Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria. Lancet, 1992, 340:1245-1248.

265. Bunnag D et al. Artemether-mefloquine combination in multidrug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89(2):213-215.

266. Karbwang J et al. A comparative clinical trial of two different regimens of artemether plus mefloquine in multidrug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89(3):296-298.

267. Looareesuwan S et al. Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria. Annals of Tropical Medicine and Parasitology, 1994, 88(2):131-136.

268. Price R et al. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(2):207-211.

269. Win LL et al. Acceptance of a short course of artesunate plus mefloquine drug combination by patients in rural Myanmar. Southeast Asian Journal of Tropical Medicine and Public Health, 1999, 30(3):418-420.

270. Nosten F et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. Journal of Infectious Diseases, 1994, 170(4):971-977. [Published erratum appears in Journal of Infectious Diseases, 1995, 171(2):519.]

271. Price R et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrobial Agents and Chemotherapy, 1999, 43(2):341-346.

272. Na-Bangchang K et al. Comparative clinical trial of four regimens of dihydroartenisinin-mefloquine in multidrug-resistant falciparum malaria. Tropical Medicine and International Health, 1999, 4(9):602-610.

273. Xu C, Ding Y, Qi Z. Efficacy of dihydroartemisinin in treatment of 37 malaria cases. Chung Hua Nei Tsa Chih, 1997, 36(3):187-189.

274. Li GQ et al. Dose findings of dihydroartemisinin in treatment of falciparum malaria. SoutheEast Asian Journal of Tropical Medicine and Public Health, 1999, 30(1):17-19.

275. Valecha N et al. Efficacy of alpha, beta-arteether in acute uncomplicated P. falciparum malaria. International Journal of Clinical Pharmacology Research, 1997, 17(1):11-15.

276. Asthana OP et al. Current status of the artemisinin derivatives in the treatment of malaria with a focus on arteether. Journal of Parasitic Diseases, 1997, 21:112.

277. Petras JM et al. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anatomy and Embryology (Berlin), 2000, 201(5):383-397.

278. Li QG et al. Pharmacology and toxicology of artelinic acid: preclinical investigations, pharmacokinetics, metabolism, protein and red blood cell binding, and anorectic toxicities. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92(3):332-340.

279. Klayman KL et al.,Transdermal artelinic acid: effective treatment for Plasmodium berghei-infected mice. American Journal of Tropical Medicine and Hygiene, 1991, 45(5):602-607.

280. Olliaro PL, Trigg PI. Status of antimalarial drugs under development. Bulletin of the World Health Organization, 1995, 73(5):565-571.

281. Schmidt LH et al. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-amino-quinoline dose. American journal of tropical medicine and hygiene, 1977, 26(6 Part 1):1116-1128.

282. Cedillos RA et al. Field evaluation of primaquine in the control of Plasmodium vivax. American Journal of Tropical Medicine and Hygiene, 1978, 27:466-472.

283. Fryauff DJ et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet, 1995, 346:1190-1193.

284. Weiss WR et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil [see comments]. Journal of Infectious Diseases, 1995, 171(6):1569-1575.

285. Shanks GD et al. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Medical Journal of Australia, 1995, 162(6):306-307, 309-310.

286. Pukrittayakamee S et al. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. Journal of Infectious Diseases, 1994, 169:932-935.

287. Wilairatana P et al. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax in Thailand. American Journal of Tropical Medicine and Hygiene, 1999, 61:973-977.

288. Gogtay NJ et al. Efficacies of 5-and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Annals of Tropical Medicine and Parasitology, 1999, 93:809-812.

289. Rowland M, Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93:641-643.

290. Beutler E. G6PD deficiency. Blood, 1994, 84:3613-3636.

291. Clyde DF, McCarthy VE. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. American Journal of Tropical Medicine and Hygiene, 1977, 26:562-563.

292. Weiss WR et al. Daily primaquine is an effective prophylaxis against falciparum malaria in Kenya. Journal of Infectious Diseases, 1995, 171:1569-1575.

293. Wernsdorfer WH, Trigg PI. Primaquine: pharmacokinetics, metabolism, toxicity, and activity. Geneva, UNDP/Word Bank/WHO special Programme for Research and Training in Tropical Diseases, 1984:164.

294. Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria in non-immume travellers: a comparison with mefloquine and doxycycline. Clinical Infectious Diseases, 1999, 29:1502-1506.

295. Anderson SL et al. Successful double-blinded, randomised, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clinical and infectious diseases, 1998, 26:146-150.

296. Shanks GD et al. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Military Medicine, 1995, 160(9):443-445.

297. Looareesuwan S et al. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 1994, 50(6):784-789.

298. Looareesuwan S et al. Randomised trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria. Acta Tropica, 1994, 57:47-53.

299. Vaillant M et al. Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Tropical Medicine and International Health, 1997, 2:917-919.

300. Kremsner PG et al. Comparison of micronised halofantrine with chloroquine antibiotic combinations for treating Plasmodium falciparum malaria in adults from Gabon. American Journal of Tropical Medicine and Hygiene, 1994, 50:790-795.

301. Pukrittayakamee S et al. Therapeutic responses to quinine and clindamycin in multidrug resistant falciparum malaria. Antimicrobial Agents and Chemotherapy 2000, 44:2395-2398.

302. De Vries PI et al. Short course of azithromycin/artesunate against falciparum malaria: no full protection against recrudescence. Tropical Medicine and International Health, 1999, 4: 407-408.

303. Na-Bangchang K et al. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. South East Asian Journal of Tropical Medicine and Public Health, 1996, 27:522-525.

304. Anderson SL et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Annals of Internal Medicine, 1995, 123:771-773.

305. Taylor WR et al. Malaria prophylaxis using azithromycin: a double-blind, placebo controlled trial in Irian Jaya, Indonesia. Clinical and Infectious Diseases, 1999, 28:74-81.

306. Radloff PD et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet, 1996, 347:1511-1514.

307. Anabwani G, Canfield CJ, Hutchinson DB. Combination of atovaquone and proguanil hydrochloride vs. halofantrine for the treatment of Plasmodium falciparum malaria in childen. Paedriatric Infectious Diseases Journal, 1999, 18(5):456-461.

308. Looareesuwan S et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine treatment of acute Plasmodium falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 1999, 60(4):526-532.

309. Lell B et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet, 1998, 351:709-713.

310. Sukwa TY et al. A randomised, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. American Journal of Tropical Medicine and Hygiene, 1999, 60(4):521-525.

311. Shanks GD et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clinical and Infectious Diseases, 1998, 27(3):494-499.

312. Hogh B et al. Atovaquone/proguanil versus chloroquine/proguanil for malaria prophylaxis in non-immune travellers: a randomised double blind study. Malarone International Study Team. Lancet, 2000, 356:1888-1894.

313. Overbosch D et al. Atovaquone/proguanil versus mefloquine for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Abstract. New Challenges in Tropical Medicine and Parasitology Conference, Oxford 18 September 2000.

314. Ndounga M et al. Variability of in vitro activity of proguanil and cycloguanil on erythrocyte stages of Plasmodium falciparum as a function of culture conditions. Bulletin de la Societé de Pathologie Exotique, 1999, 92(5):313-316.

315. Astra-Zeneca. Marketing authorisation application to use Savarine for the short term chemoprophylaxis of malaria. Clinical expert report. 1999:10-13 (Dossier NL21155).

316. Sarrouy J et al. Chimoprophylaxie du paludisme à Plasmodium falciparum par une association de 100 mg de chloroquine et de 200 mg de proguanil par jour dans une zone III de chloroquino-résistance (Gabon). Bulletin de la Societé de Pathologie Exotique, 1991, 84:80-93.

317. Looareesuwan S et al. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 1999, 60(2):238-243.

318. van Vugt M et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrobial Agents and Chemotherapy, 1998, 42(1):135-139.

319. von Seidlein L et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. Journal of Infectious Diseases, 1997, 176(4):1113-1116.

320. A randomised, double-blind, parallel group trial comparing efficacy, safety and pharmacokinetics of the standard schedule (4 ? 4 tablets over 48 hours) with two higher dose schedules of co-artemether in the treatment of acute Plasmodium falciparum malaria in adults and children in Thailand. Basle, Novartis Pharma AG, 1997.

321. van Vught M et al. The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol). Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92:564-565.

322. Tamariya P et al. In vitro sensitivity of Plasmodum falciparum and clinical response to lumefantrine (benflumetol) and artemether. British Journal of Clinical Pharmacology, 2000, 49(5):437-444.

323. van Vught M et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in the treatment of multi-drug resistant falciparum malaria. American Journal of Tropical Medicine and Hygiene, 1999, 60(6):936-942.

324. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemetherlumefantrine. Clinical pharmacokinetics, 1999, 37(2): 105-125.

325. Coartem tablets (CGP 56697, co-artemether). Integrated summary of safety (ISS). Basle, Novartis Pharma AG, 1998.

326. van Vught M et al. No evidence of cardiotoxicity during antimalarial treatment with artemetherlumefantrine. American Journal of Tropical Medicine and Hygiene, 1999, 61(6):964-967.

327. Riekmann K et al. Response of Plasmodium falciparum infections to pyrimethamine-sulphadoxine in Thailand. American Journal of Tropical Medicine and Hygiene, 1987, 37:211-216.

328. White NJ. Combination treatment for falciparum prophylaxis. Lancet, 1987, 1:680-681.

329. White NJ. Antimalarial drug resistance: the pace quickens. Journal of Antimicrobial Chemotherapy, 1992, 30:571-585.

330. Nosten F et al. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet, 1991, 337:1140-1143.

331. Fivelman QL et al. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93:429-432.

332. McIntosh HM, Greenwood BM. Chloroquine or amodiaquine combined with sulphadoxine-pyrimethamine as a treatment for uncomplicated malaria - a systematic review. Annals of Tropical Medicine and Parasitology, 1998, 93(3):265-270.

333. Nzila MA et al. Towards an understanding of the mechanism of pyrimethamine/sulfadoxine resistance in Plasmodium falciparum: the genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antmicrobial Agents and Chemotherapy, 2000, 44(4):991-996.

334. Reeder JC et al.,Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 1996, 55:209-213.

335. Diourte Y et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. American Journal of Tropical Medicine and Hygiene, 1999, 60:475-478.

336. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaoundé, Cameroon. Vl. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. American Journal of Tropical Medicine and Hygiene, 2000, 62: 271-276.

337. Mokherjee S et al. Analysis in yeast of Plasmodium falciparum low frequency dihydrofolate reductase alleles isolated from polyclonal patient samples. American Journal of Tropical Medicine and Hygiene, 1999, 61:131-140.

338. Watkins WM et al. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitology Today, 1997, 13:459-464.